An Efficient Transgenesis Approach for Gene Delivery in the Mouse Embryonic Heart
May 24th, 2024
This protocol presents a detailed methodological framework for electroporation-based transgenesis of cardiac cells in developing mouse hearts. The video assets provided here will facilitate learning of this versatile technique.
We aim to establish a new methodology that facilitates the overexpression or downregulation of a certain gene to understand heart development. Mouse transgenesis is a great investment of time and effort. Assessing genes one by one is not realistic because of this and also because of the high complexity of the genome.
Hence, there is a need for a rapid method of screening. We have presented a tool available to any researcher to analyze the gain or loss of function of a candidate gene during heart development. The main advantage of our protocol is that it's much quicker and less expensive than mouse transgenesis.
Perhaps it could be used to assess different genes of interest before commencing a transgenesis experiment. To begin, use a pipette puller to stretch a 20-micrometer wide glass capillary. Place an extracted mouse uterus on a dry paper towel, then insert the tip of a pair of fine scissors into the mesometrial side of the uterus, and slowly run the edge of the blade through the whole length and cut it.
Now expose and cut the decidui. Transfer them into a dish with growth medium. Dissect the decidui to extract the embryos.
Transfer the embryos into a 60-millimeter Petri dish containing warm growth medium. With a pair of fine forceps, carefully cut the tail and the head of the embryo and leave only the trunk of the body. Carefully remove as much tissue as possible from the trunk without damaging the heart or pulmonary and aorta arteries.
Insert a new stretched-out needle into the tip of the mouth pipette and carefully aspirate and load 10 microliters of a prepared plasmid mix into the stretched-out needle. Place a single heart into a clean 60-millimeter Petri dish containing prewarmed PBS. Place the dish under a dissecting microscope.
Adjust the distance between the poles of positive and negative electrodes to about four millimeters. Next, use a needle in a mouth pipette to gently puncture the most superficial layer of the heart. Transfer one to two microliters of the plasmid mix into the heart;remove the needle carefully.
Hold the electrode in place so that the heart is located between both poles, then electroporate the heart. Transfer the electroporated heart to a new 12-well plate containing one milliliter of growth medium. Incubate the plate at 37 degrees Celsius under 5%carbon dioxide until analysis.
To begin, obtain electroporated mouse hearts extracted from wild type CD-1 mice 12 to 12.5 days after crossing. Transfer a heart into a tube containing one milliliter of ice-cold digestion medium. With a syringe apply gentle pressure on the heart a few times to chop it.
Incubate the chopped tissue on a hot plate at 37 degrees Celsius for 45 minutes at 600 rotations per minute, then filter the digestion mixture through a 70-micrometer cell strainer into a new tube. Next, filter the pass-through volume again with a 40-micrometer cell strainer into a new 50-milliliter tube. Pipette 500 microliters of the FBS into the filtrate.
Make up the volume up to 30 milliliters with cold DMEM. Centrifuge the suspension at 240 g for 10 minutes at room temperature. Discard the supernatant, then place the tube upside down on a paper towel to dry completely.
For cell sorting, resuspend the cells in 300 microliters of sorting buffer. Finally, add 0.3 microliters of DAPI and perform cell sorting. The hearts were beating and appeared to be in good condition.
24 hours post electroporation. The myocardium and epicardium did not show any signs of apoptosis. Analysis of the fluorescence activity showed a mosaic GFP signal in almost all four chambers of the heart.
Overview
This protocol presents a new methodology for gene manipulation in cardiac cells of developing mouse hearts. It allows for rapid screening of gene function, facilitating the understanding of heart development.
Key Study Components
Area of Science
- Cardiac Development
- Transgenesis
- Gene Regulation
Background
- Understanding heart development requires analyzing gene functions.
- Traditional mouse transgenesis is time-consuming and costly.
- There is a need for efficient methods to assess gene function.
- This protocol aims to address these challenges.
Purpose of Study
- To establish a rapid method for gene overexpression or downregulation.
- To facilitate the analysis of candidate genes during heart development.
- To provide a cost-effective alternative to traditional transgenesis.
Methods Used
- Electroporation-based transgenesis technique.
- Application in developing mouse hearts.
- Video assets for instructional support.
- Screening for gain or loss of function of genes.
Main Results
- The protocol is quicker and less expensive than traditional methods.
- It allows for efficient screening of gene functions.
- Facilitates understanding of complex gene interactions in heart development.
- Accessible to researchers for further studies.
Conclusions
- This methodology enhances the study of cardiac gene functions.
- It provides a valuable tool for researchers in the field.
- Encourages further exploration of heart development mechanisms.
Frequently Asked Questions
Executive Industry Relevance
Rapid gene delivery and functional screening in embryonic mouse hearts addresses a critical bottleneck in early cardiovascular target validation. This approach enables efficient interrogation of gene function, supporting predictive confidence and mechanistic de-risking before resource-intensive transgenic model generation. The method streamlines portfolio triage and accelerates decision-making at key discovery inflection points.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid gain- and loss-of-function analysis for candidate cardiac genes.
- Supports mechanistic de-risking by clarifying gene roles in heart morphogenesis.
- Facilitates functional target validation prior to full transgenic model investment.
- Improves predictive confidence for prioritizing gene targets in cardiovascular research.
Screening & Assay Development
- Prepares validated embryonic heart systems for downstream phenotypic screening.
- Delivers reproducible, quantitative readouts via mosaic GFP expression in cardiac tissue.
- Enables scalable, cost-effective screening of multiple gene candidates.
- Supports assay standardization and platform reuse for gene function studies.
Translational & Preclinical Research
- Aligns early gene function data with disease-relevant cardiac development pathways.
- Provides continuity from discovery through preclinical validation of cardiac targets.
- Reduces risk of late-stage failure by enabling early functional assessment.
- Supports translational biomarker identification when gene effects are phenotypically measurable.
Pipeline & Workflow Integration
This electroporation-based gene delivery method fits between early discovery and preclinical model development, enabling rapid hypothesis testing and target prioritization in cardiac research pipelines.
- Discovery Biology: Accelerates hypothesis testing and pathway clarification for cardiac gene candidates.
- Screening: Provides reproducible, quantitative outputs for comparative gene function analysis.
- Analytics: Enables measurement of gene expression and phenotypic effects across heart chambers.
- Translational Research: Bridges early discovery with preclinical validation by modeling gene effects in embryonic heart tissue.
- Enterprise Reuse: Offers a reusable platform for rapid gene function assessment across multiple cardiac targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac target validation.
- Operational Value: Delivers standardized, reproducible, and scalable gene delivery for functional screening.
- Strategic Value: Enables faster go/no-go decisions and improves capital efficiency in early-stage cardiovascular research.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of cardiac gene targets.
Implementation Considerations
- Requires expertise in embryonic dissection and electroporation techniques.
- Needs access to specialized instrumentation for microinjection and cell sorting.
- Demands cross-team standardization for reproducibility and data comparability.
- May require adaptation for different developmental stages or cardiac regions.
- Limited to transient gene expression; not a substitute for stable transgenic models when long-term studies are needed.
